文献速递造血干细胞移植与细胞治疗淋巴瘤

CD70可识别同种异体反应性T细胞,并是预防和治疗急性GVHD的潜在靶点

CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD.
PubMed 文献 · Blood Adv · 2024-01-01

本研究探讨异基因造血干细胞移植(allo-HSCT)后早期T细胞CD70表达的功能与临床意义,发现CD70在移植后2周内高活化记忆T细胞亚群表达,CD70+ T细胞呈MYC驱动糖酵解和增殖转录特征,急性GVHD(aGVHD)时CD4+和CD8+CD70+ T细胞数量分别增加9倍和4倍,体外CD70阻断可减弱增殖和炎性细胞因子反应。

要点

  • 移植后2周内CD70表达于高活化记忆T细胞亚群,随后在多数患者中逐渐下降。
  • aGVHD时CD4+和CD8+CD70+ T细胞数量分别增加9倍和4倍,呈寡克隆TCR repertoire。
  • 体外CD70阻断可明显减弱CD70+ T细胞的增殖和炎性细胞因子反应。

核心结论

  • CD70是高活化同种异体反应性T细胞的标志物,抑制CD27-CD70共刺激在aGVHD预防和治疗中具有潜在治疗重要性。

研究设计与样本

  • 研究探讨allo-HSCT后早期T细胞CD70表达的功能与临床意义,包括移植后早期患者样本分析及体外功能实验。

主要发现

  • CD70在移植后2周内表达于高活化记忆T细胞亚群,随后在多数患者中逐渐下降。
  • CD70+ T细胞呈开放染色质景观和提示MYC驱动糖酵解和增殖的转录谱。
  • aGVHD时CD4+和CD8+CD70+ T细胞数量分别增加9倍和4倍,呈寡克隆TCR repertoire。
  • CD70+ T细胞表达CCR4和CCR6趋化因子受体,在aGVHD组织样本中明显增多。
  • 体外CD70+ T细胞显示同种异体反应特异性,CD70阻断可明显减弱增殖和炎性细胞因子反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) remains a major challenge after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and further understanding of its immunopathology is crucial for developing new treatments. CD70 interacts with CD27 and is upregulated transiently on T cells after recent T-cell receptor (TCR) engagement. Here, we investigated the functional and clinical significance of CD70 expression on T cells during the early posttransplantation period. CD70 was expressed on a subset of highly activated memory T cells within the first 2 weeks after transplant, which then gradually declined in most patients. CD70+ T cells exhibited an open chromatin landscape and a transcriptional profile indicative of intense Myelocytomatosis oncogene (MYC)-driven glycolysis and proliferation. CD4+ and CD8+CD70+ T-cell numbers increased by ninefold and fourfold, respectively, during acute GVHD (aGVHD) and displayed an oligoclonal TCR repertoire. These cells expressed CCR4 and CCR6 chemokine receptors and were markedly increased in aGVHD tissue samples. Furthermore, CD70+ T cells demonstrated alloreactive specificity in vitro, and proliferative and inflammatory cytokine responses were markedly attenuated by CD70 blockade. These findings identify CD70 as a marker of highly activated alloreactive T cells and reveal the potential therapeutic importance of inhibiting CD27-CD70 costimulation in both the prophylaxis and treatment of aGVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Verma K, Croft W, Margielewska-Davies S, et al. CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD. Blood Adv. 2024. PMID: 39028952. doi:10.1182/bloodadvances.2024012909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。